文献速递冠心病

桡动脉与股动脉入路对死亡和大出血影响的个体患者数据荟萃分析

Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials.
PubMed 文献 · Circulation · 2022-08-29

结果显示TRA组全因死亡(1.6% vs 2.1%;HR 0.77,95%CI 0.63-0.95;P=0.012)和大出血(1.5% vs 2.7%;OR 0.55,95%CI 0.45-0.67;P<0.001)均低于TFA组,死亡获益在中重度贫血患者中显著,大出血减少仅部分解释死亡获益。

要点

  • TRA较TFA降低30天全因死亡(HR 0.77)和大出血(OR 0.55)。
  • 死亡获益在中重度贫血患者中显著,轻度或无贫血者不显著。
  • 大出血减少仅部分介导死亡获益,需其他机制解释。

核心结论

  • 与TFA相比,TRA与30天全因死亡和大出血风险降低相关。
  • TRA的死亡获益主要由贫血患者驱动。
  • 大出血减少仅部分解释TRA的死亡获益。

研究设计与样本

  • 研究设计为多中心随机临床试验的个体患者数据荟萃分析。
  • 中位年龄63.9岁,女性占31.9%,95%表现为急性冠脉综合征,75.2%接受PCI。
  • 主要分析采用一阶段混合效应模型,基于意向性治疗人群。

主要发现

  • TRA组全因死亡率为1.6%,TFA组为2.1%(HR 0.77,95%CI 0.63-0.95;P=0.012)。
  • TRA组大出血发生率为1.5%,TFA组为2.7%(OR 0.55,95%CI 0.45-0.67;P<0.001)。
  • 死亡亚组分析除基线血红蛋白水平外结果一致(交互P=0.003),中重度贫血患者TRA获益显著,轻度或无贫血者不显著。
  • 多变量调整后,TRA仍与全因死亡相对风险降低24%和大出血相对风险降低51%相关。
  • 中介分析显示TRA的死亡获益仅部分由大出血预防驱动,需辅助机制解释因果关系。

临床怎么用

  • 在冠脉造影或PCI患者中,可优先考虑经桡动脉入路以降低30天死亡和大出血风险。
  • 对于合并中重度贫血的患者,TRA的死亡获益可能更为明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In some randomized clinical trials, transradial access (TRA) compared with transfemoral access (TFA) was associated with lower mortality in patients with coronary artery disease undergoing invasive management. We analyzed the effects of TRA versus TFA across multicenter randomized clinical trials and whether these associations are modified by patient or procedural characteristics. METHODS: We performed an individual patient data meta-analysis of multicenter randomized clinical trials comparing TRA with TFA among patients undergoing coronary angiography with or without percutaneous coronary intervention. The primary outcome was all-cause mortality and the co-primary outcome was major bleeding at 30 days. The primary analysis was conducted by 1-stage mixed-effects models on the basis of the intention-to-treat cohort. The effect of access site on mortality and major bleeding was assessed further by multivariable analysis. The relationship among access site, bleeding, and mortality was investigated by natural effect model mediation analysis with multivariable adjustment. RESULTS: A total of 21 600 patients (10 775 TRA, 10 825 TFA) from 7 randomized clinical trials were included. The median age was 63.9 years, 31.9% were women, 95% presented with acute coronary syndrome, and 75.2% underwent percutaneous coronary intervention. All-cause mortality (1.6% versus 2.1%; hazard ratio, 0.77 [95% CI, 0.63-0.95]; P=0.012) and major bleeding (1.5% versus 2.7%; odds ratio, 0.55 [95% CI, 0.45-0.67]; P<0.001) were lower with TRA. Subgroup analyses for mortality showed consistent results, except for baseline hemoglobin level (Pinteraction=0.003), indicating that the benefit of TRA was substantial in patients with moderate or severe anemia, whereas it was not significant in patients with milder or no baseline anemia. After adjustment, TRA remained associated with 24% and 51% relative risk reduction of all-cause mortality and major bleeding, respectively. A mediation analysis showed that the benefit of TRA on mortality was only partially driven by major bleeding prevention and ancillary mechanisms are required to fully explain the causal association. CONCLUSIONS: TRA is associated with lower all-cause mortality and major bleeding at 30 days compared with TFA. The effect on mortality was driven by patients with anemia. The reduction in major bleeding only partially explains the mortality benefit. REGISTRATION: URL: https://www.crd.york.ac.uk/prospero; Unique identifier: CRD42018109664.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Gargiulo, Giacoppo, Jolly, et al. Effects on Mortality and Major Bleeding of Radial Versus Femoral Artery Access for Coronary Angiography or Percutaneous Coronary Intervention: Meta-Analysis of Individual Patient Data From 7 Multicenter Randomized Clinical Trials. Circulation. 2022. PMID: 36036610. doi:10.1161/CIRCULATIONAHA.122.061527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。